Yi Feng1,#, Haoxin Yang2, Guicai Liang1, Jun Chen3, Tao Li1, Yingjuan Wang4, Jilin Chang1, Yan Li3, Meng Yang1, Xilong Zhou1, Zhiqiang Wang5,*, Chunlei Ge1,*
Oncology Research, Vol.33, No.12, pp. 3801-3836, 2025, DOI:10.32604/or.2025.067824
- 27 November 2025
Abstract Immune checkpoint inhibitor (ICI) has limited efficacy in the treatment of immune “cold” tumors. Due to insufficient T cell infiltration and heterogeneous programmed death ligand 1 (PD-L1) expression, the ORR is only 5%–8% compared with 30%–40% of “hot” tumors. This article reviews the synergistic mechanism, clinical efficacy and optimization strategy of oncolytic virus (OVs) combined with ICIs in the treatment of refractory malignant tumors. Systematic analysis of mechanistic interactions across tumor types and clinical trial data demonstrates that OVs transform the immunosuppressive microenvironment by inducing immunogenic cell death and activating innate immunity. Concurrently, ICIs enhance… More >